Navigation Links
Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
Date:9/19/2011

ANAHEIM, Calif., Sept. 19, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Jefferies Global Healthcare Conference to be held September 27-28, 2011 in London.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Wednesday, September 28, 2011 at 8:00 a.m. BST.  Mr. Bailey will utilize the Company's investor presentation that was previously filed with the U.S. Securities and Exchange Commission on September 12, 2011 under Form 8-K.

"This will be our first investor conference in Europe," commented Mr. Bailey.  "While Questcor's primary product, H.P. Acthar® Gel (repository corticotropin injection), is not approved for marketing outside of the United States, we look forward to discussing Questcor with European investors as we continue to experience growth of both prescriptions and net sales in our multiple sclerosis exacerbation and nephrotic syndrome markets."

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for ninety days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  For more information, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our net sales and profits;
  • Reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician recommendations;
  • Our ability to generate revenue from sales of Acthar to treat on-label indications associated with NS;
  • Regulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits;
  • Our ability to receive high reimbursement levels from third party payers;
  • An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities;
  • Our ability to effectively manage our growth, including the expansion of our NS selling effort;
  • Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2010, and other documents filed with the Securities and Exchange Commission.

The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date of this release.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports Solid Fourth Quarter Results
2. Questcor to Discuss Results From FDA Panel Meeting
3. Trading Halted Today in Questcor Pharmaceuticals Common Stock
4. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
5. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Questcor to Present at UBS Global Life Sciences Conference
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
11. Questcor Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... , Feb. 19, 2017  nThrive™, an independent ... portfolio and thought leadership at the 2017 HIMSS ... category leader award from KLAS. nThrive ... focused on how market trends shape the holistic, ... a sophisticated, comprehensive Patient Access solution. The panel ...
(Date:2/18/2017)... 17, 2017   Parker Waichman LLP, ... rights of victims injured by medical devices, comments ... call for better reporting. Congress required hospitals to ... concerns involving power morcellators and duodenoscopes prompted the ... how hospitals report injuries and deaths related to ...
(Date:2/17/2017)... 17, 2017 Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, ... global ablation technologies market is expected to grow at a CAGR ... market is expected to grow at a CAGR of 9.5% from ... and $9.05bn in 2026. ... How this report will benefit you Read on to ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... ... The StayWell Company and VUCA Health announced today ... foster behavior change and improve health literacy among patients. VUCA Health, which created and ... its video capability at StayWell booth 3443 during HiMSS. , The VUCA library ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies ... by for a visit this week at HIMSS 2017 Conference & Exhibition. The ... the globe. Sensogram will be featured in the conference’s Connected Health Experience section, ...
(Date:2/20/2017)... Sunapee, NH (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software ... rapid growth of the company. The new location will triple the size of the ... location for the town of Sunapee, NH. , “We are excited to expand ...
(Date:2/20/2017)... St. Petersburg, Fla. (PRWEB) , ... February 20, 2017 , ... ... of its research and education building. A topping out ceremony on Friday marked the ... , The building, set to open in Fall 2018, will serve as a center ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... eye care providers and health plan partners, announced during the 2017 Annual ... success enhancing care coordination for diabetic patients and integrating eye care into ...
Breaking Medicine News(10 mins):